Non-hormonal menopause antibody validates AI-enabled drug discovery

Conviction: 58% · Horizon: 2Y · 2026-08-10
Monthly ABCL635 can take share in a multi-billion vasomotor-symptom market

Phase 2 data for ABCL635 showed an 83% reduction in moderate-to-severe hot-flash frequency at week 4 versus 33% on placebo, a statistically significant 50-point placebo-adjusted gap. A once-monthly injectable would compete with daily oral non-hormonal options in a large menopause market, and a cash-rich balance sheet can fund Phase 3 without an emergency raise. The equity still prices more like a discovery-platform option than a de-risked late-stage asset.

Themes

COIN CRCL Stablecoins 2026-08-12
ABCL AI Drug Discovery 2026-08-12

The content on this page is for informational purposes only and does not constitute financial advice. Stoquate is not a licensed financial advisor. Always conduct your own research and consult a qualified professional before making any investment decisions.